Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma

Bone Marrow Transplantation

Volumn 39, Issue 11, 2007, Pages 695-703

  Meehan, K R ^a   Wu, J ^a   Bengtson, E ^a   Hill, J ^a   Ely, P ^a   Szczepiorkowski, Z ^a   Kendall, M ^a   Ernstoff, M S ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BORTEZOMIB; CALCIUM CHANNEL BLOCKING AGENT; CARMUSTINE; CD3 ANTIGEN; CIPROFLOXACIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MELPHALAN; PENICILLIN G; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CARDIOVERSION; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DEPRESSION; DIARRHEA; DIURESIS; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EFFECTOR CELL; FATIGUE; FEMALE; FLUID RETENTION; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HEART ATRIUM FIBRILLATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTENSION; IMMUNE DEFICIENCY; LUNG TOXICITY; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA CELL; NAUSEA; NEUTROPHIL; PRIORITY JOURNAL; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTE; VASCULAR DISEASE; VOMITING;

AGED; CD4 LYMPHOCYTE COUNT; CELL SURVIVAL; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECOVERY OF FUNCTION; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 34249319469     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705665     Document Type: Article

References (40)

1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
2. Child J, Morgan G, Davies F, Owen R, Bell S, Phil D et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New Eng J Med 2003; 348: 1875-1883.
3. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-854.
4. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001; 24: 363-373.
5. Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and antigen presenters: How lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 2005; 26: 111-117.
6. Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98: 579-585.
7. Powles R, Singhal S, Treleaven J, Kulkarni S, Horton C, Mehta J. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood 1998; 91: 3481-3486.
8. Pavletic ZS, Joshi SS, Pirruccello SJ, Tarantolo SR, Kollath J, Reed EC et al. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. Bone Marrow Transplant 1998; 21: 33-41.
9. Maurizio M, Chiriva-Internati, Du J, Cannon M, Barlogie B, Yi Q et al. Myeloma-reactive allospecific cytotoxic T lymphocytes lyse target cells via the granule exocytosis pathway. Br J Haemat 2001; 112 410-420.
10. Wen Y, Barlogie B, Yi Q. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: Evidence for their capacity to lyse autologous primary tumor cells. Blood 2001; 97: 1750-1755.
11. Hayashi T, Hideshima T, Akiyama M, Raje N, Richardson P, Chauhan D et al. Ex vivo expansion of multiple myeloma-specific cytotoxic T lymphocytes. Blood 2003; 102: 1435-1442.
12. + cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2001; 7: 216-222.
13. + NKT cells in the treatment of lymphoma. Biol Blood Marrow Transplant 2001; 7: 532-542.
14. Meehan KR, Verma UN, Rajogopal C, Cahill R, Frankel S, Mazumder A. Stem cell transplantation with chemoradiotherapy myeloablation and interleukin-2. J Infus Chemother 1996; 6: 28-32.
15. Meehan KR, Verma UN, Cahill R, Frankel S, Areman EM, Sacher RA et al. Interleukin-2 activated hematopoietic stem cell transplantation for breast cancer: Investigation of dose level with clinical correlates. Bone Marrow Transplant 1997; 20: 643-651.
16. Meehan KR, Badros A, Frankel SR, Cahill R, Areman E, Jenson M et al. A pilot study evaluating IL-2 activated hematopoietic stem cell transplantation for hematologic malignancies. J. Hematotherapy 1997; 6: 457-464.
17. Verma UN, Meehan KR, Mazumder A. Post-bone marrow transplant use of immunotherapy. Cancer Treat Res 1997; 77: 27-55.
18. Meehan KR, Arun B, Gehan EA, Berberian B, Sulica V, Areman EM et al. Immunotherapy with interleukin-2 and alpha-interferon following IL-2 activated hematopoietic stem cell transplantation for breast cancer. Bone Marrow Transplant 1999; 23: 667-673.
19. Porrata LF, Gertz MA, Geyer SM, Litzow MR, Gastineau DA, Moore SB et al. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood heamtopoietic stem cell transplantation in multiple myeloma. Leukemia 2004; 18: 1085-1092.
20. Kay NE, Leong TL, Bone N, Vesole DH, Greipp PR, Ness BV et al. Blood levels of immune cells predict survival in myeloma patients: Results of an Eastern Cooperative Oncology Group phase III trial for newly diagnosed multiple myeloma patients. Blood 2001; 98: 23-28.
21. Ito M, Shizuru J. Graft-vs-Lymphoma effect in an allogeneic hematopoietic stem cell transplantation model. Biol Blood Marrow Transplant 1999; 5: 357-368.
22. Rosinski SL, McNiece IK, Shpall EJ, Clough N, Russell P, Blunk B et al. Prognostic analysis of pre-transplant peripheral T-cell levels in patients receiving an autologous hematopoietic progenitor-cell transplant. Bone Marrow Transplant 2005; 36: 425-430.
23. Hess AD, Bright EC, Thoburn C, Vogelsang GB, Jones RJ, Kennedy MJ. Specificity of effector T lymphocytes in autologous graft-versus-host disease: Role of the major histocompatibility complex class II invariant chain peptide. Blood 1997; 89: 2203-2209.
24. Porrata LF, Gertz MA, Litzow MR, Lacy MQ, Dispenzieri A, Inwards DJ et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res 2005; 11: 1210-1218.
25. Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, Fleisher TA et al. Lymphopenia and interleukin-2 therapy alter hemostasis of CD4+ CD25+ regulatory T cells. Nat Med 2005; 11: 1238-1243.
26. Wang L, Shu S, Plautz G. Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells. Cancer Res 2005; 65: 9547-9554.
27. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D et al. IL-2 regulates FOXP3 expression in human CD4+ CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006; 108: 1571-1579.
28. Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999; 17: 2521-2529.
29. Hellstrom KE, Hellstrom I, Kant JA, Tamerius JD. Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population. J Exp Med 1978; 148: 799.
30. Kirkwood JM. Systemic therapy of melanoma. Curr Opin Oncol 1994; 6: 204-211.
31. Massumoto C, Benyunes MC, Sale G, Beauchamp M, York A, Thompson JA et al. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy. Bone Marrow Transplant 1996; 17: 351-356.
32. Robinson N, Benyunes MC, Thompson JA, York A, Petersdorf S, Press O et al. Interleukin-2 after autologous stem cell transplantation for hematologic malignancies: A phase I/II study. Bone Marrow Transplant 1997; 19: 435-442.
33. Fefer A, Robinson N, Benyunes MC, Bensinger WI, Press O, Thompson JA et al. Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies. Cancer J Sci Am 1997; 3 (Suppl 1): S48-S53.
34. deMagalhaes-Silverman M, Donnenberg A, Lembersky B, Elder E, Lister J, Rybka W et al. Post transplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. J Immunother 2000; 23: 154-160.
35. Vivancos P, Granena Jr A, Sarra J, Granena A. Treatment with interleukin-2 (IL-2) and interferon (IFN-alpha 2b) after autologous bone marrow or peripheral blood stem cell transplantation in onco-hematological malignancies with a high risk of relapse. Bone Marrow Transplant 1999; 23: 169-172.
36. Maraninchi D, Vey N, Viens P, Stoppa AM, Archimbaud E, Attal M et al. A Phase II study of IL-2 in 49 pts with relapsed or refractory leukemia. Leuk Lymphoma 1998; 31: 343-349.
37. Ragnhammar P, Frodin JE, Trotta PP, Mellstedt H. Cytotoxicity of white cells activated by granulocyte-colony stimulating factor, GM-CSF and macrophage-CSF against tumor cells in the presence of various monoclonal antibodies. Cancer Immunol Immunother 1994; 39: 254-262.
38. Spitler LE, Grossbard ML, Ernstoff MS, Silver G, Jacobs M, Hayes FA et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000; 18: 1614-1621.
39. Wing EJ, Magee DM, Whiteside TL, Kaplan SS, Shadduck RK. Recombinant human granulocyte-macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients. Blood 1989; 73: 643-646.
40. Gazitt Y. Immunologic profiles of effector cells and peripheal blood stem cells mobilized with different hematopoietic growth factors. Stem Cells 2001; 18: 390-398.